$MESO News

Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Full Transcript: Mesoblast FY 2026 Earnings Call

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals

Reported Earlier, Mesoblast Reaches Patient Recruitment Target In Phase 3 Trial For Non-Opioid Chronic Low Back Pain Therapy

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform

Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in

Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why